[News] San Antonio Breast Cancer Symposium 2017
Debu Tripathy (University of Texas MD Anderson Cancer Center, Houston, TX, USA) and colleagues presented an interim analysis of the randomised, phase 3, MONALEESA-2 trial, the first trial investigating the addition of cyclin D1/CDK4/6 inhibitor ribociclib to standard hormone therapy in women with premenopausal or perimenopausal, hormone receptor –positive (HR-positive), HER2-negative advanced breast cancer. 672 patients were randomly assigned (1:1) to ribociclib (600 mg per day, 3-weeks on, 1-week off; n=335) or placebo (n=337) in combination with tamoxifen (20 mg per day) or a nonsteroidal aromatase inhibitors (letrozol...
Source: The Lancet Oncology - December 14, 2017 Category: Cancer & Oncology Authors: Roxanne Nelson Tags: News Source Type: research
[News] 2017 ASH Meeting
Youn H Kim (Stanford University, Stanford, CA, USA) presented results from MAVORIC, an open-label, international, randomised, phase 3 trial comparing mogamulizumab (an anti-chemokine receptor 4 antibody) with vorinostat in 372 patients with previously treated cutaneous T-cell lymphoma. Investigator-assessed progression-free survival (primary endpoint) was significantly longer with mogamulizumab than with vorinostat (median 7 ·7 months [95% CI 5·7–10·3] vs 3·1 months [2·9–4·1]; hazard ratio [HR] 0·53 [95% CI 0·41–0·69]; p (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 14, 2017 Category: Cancer & Oncology Authors: Farhat Yaqub Tags: News Source Type: research
[Articles] Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
BAT is a safe therapy that resulted in responses in asymptomatic men with metastatic castration-resistant prostate cancer and also resensitisation to enzalutamide in most patients undergoing rechallenge. Further studies with BAT are needed to define the potential clinical role for BAT in the management of metastatic castration-resistant prostate cancer and the optimal strategy for sequencing between androgen and antiandrogen therapies in metastatic castration-resistant prostate cancer to maximise therapeutic benefit to patients. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 13, 2017 Category: Cancer & Oncology Authors: Benjamin A Teply, Hao Wang, Brandon Luber, Rana Sullivan, Irina Rifkind, Ashley Bruns, Avery Spitz, Morgan DeCarli, Victoria Sinibaldi, Caroline F Pratz, Changxue Lu, John L Silberstein, Jun Luo, Michael T Schweizer, Charles G Drake, Michael A Carducci, C Tags: Articles Source Type: research
[Comment] Bipolar androgen therapy: an intriguing paradox
In The Lancet Oncology, Benjamin A Teply and colleagues1 report a phase 2 trial in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor pathway inhibitor, enzalutamide, who were treated with bipolar androgen therapy (BAT). It is a novel and intriguing concept. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 13, 2017 Category: Cancer & Oncology Authors: Christopher P Evans Tags: Comment Source Type: research
[Articles] Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
The results of this interim analysis show that venetoclax has durable clinical activity and favourable tolerability in patients with relapsed or refractory chronic lymphocytic leukaemia whose disease progressed during or after discontinutation of ibrutinib therapy. The durability of response to venetoclax will be assessed in the final analysis in 2019. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 12, 2017 Category: Cancer & Oncology Authors: Jeffrey A Jones, Anthony R Mato, William G Wierda, Matthew S Davids, Michael Choi, Bruce D Cheson, Richard R Furman, Nicole Lamanna, Paul M Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod A Humerickhouse, Jalaja Potluri, Steven Coutre Tags: Articles Source Type: research
[Comment] Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib
In recent years, biological and clinical research has identified several targeted agents that are changing the management of patients with chronic lymphocytic leukaemia. In clinical trials,1 the B-cell receptor inhibitor ibrutinib has led to durable responses and longer survival (overall and progression-free) than chemotherapy in patients with this disease. Ibrutinib is now largely used in clinical practice in patients with chromosome 17p deletions or TP53 mutations and relapsed or refractory chronic lymphocytic leukaemia. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 12, 2017 Category: Cancer & Oncology Authors: Francesca R Mauro, Robin Fo à Tags: Comment Source Type: research
[Articles] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered —eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 11, 2017 Category: Cancer & Oncology Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Tags: Articles Source Type: research
[Comment] Neoadjuvant chemotherapy in breast cancer: more than just downsizing
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) has established a new milestone in evidence-based treatment for early breast cancer. Through longstanding collaboration, mutual trust, and data transparency, they have gathered individual patient data for 4756 women randomly allocated in ten trials to either neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy, with a median follow-up of 9 years (IQR 5 –14). The results of this meta-analysis,1 published in The Lancet Oncology, substantiate that NACT results in higher rates of breast-conserving therapy than does adjuvant chemotherapy (rate ratio 1·28 [95...
Source: The Lancet Oncology - December 11, 2017 Category: Cancer & Oncology Authors: Marloes G M Derks, Cornelis J H van de Velde Tags: Comment Source Type: research
[Articles] Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed, and was also associated with a survival benefit in HER2-positive breast cancer and TNBC. By contrast, increased TILs were an adverse prognostic factor for survival in luminal –HER2-negative breast cancer, suggesting a different biology of the immunological infiltrate in this subtype. Our data support the hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 7, 2017 Category: Cancer & Oncology Authors: Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang D Schmitt, Jens-Uwe Blohmer, Thomas Karn, Berit M Pfitzner, Sherko Tags: Articles Source Type: research
[News] Combined androgen blockade for salivary gland carcinoma
Combined androgen blockade with leuprorelin acetate and bicalutamide could be equally effective and less toxic than conventional chemotherapy for patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma, according to a recent study. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 7, 2017 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research
[News] BGJ398 for FGFR-altered advanced cholangiocarcinoma
Results from a single-arm, multicentre, phase 2 trial suggest that patients with advanced cholangiocarcinoma with genetic alterations in fibroblast growth factor receptor (FGFR) might respond to treatment with BGJ398, a first-in-class selective pan-FGFR kinase inhibitor. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 7, 2017 Category: Cancer & Oncology Authors: Judith A Gilbert Tags: News Source Type: research
[Comment] Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance
The immune microenvironment is now recognised as crucial in the treatment of cancer. The tumour immune infiltrate has been noted to be associated with better outcomes in HER2-positive breast cancer and triple-negative breast cancer (TNBC), in both the early-stage and the advanced disease setting.1,2 Incorporating the quantity of the pre-existing immune response with other prognostic clinical pathological factors, such as tumour size and nodal status, will allow clinicians to better estimate long-term survival after breast cancer diagnosis. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 7, 2017 Category: Cancer & Oncology Authors: Roberto Salgado, Sherene Loi Tags: Comment Source Type: research
[Articles] Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
The safety profile of buparlisib plus fulvestrant does not support its further development in this setting. Nonetheless, the efficacy of buparlisib supports the rationale for the use of PI3K inhibitors plus endocrine therapy in patients with PIK3CA mutations. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 6, 2017 Category: Cancer & Oncology Authors: Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per E L ønning, Wolfgang Janni, Ruth O'Regan, Marie-Ange Mouret-Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C G Tjan-Heijnen, Sibel Blau, Ale Tags: Articles Source Type: research
[Articles] Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Avelumab showed antitumour activity in the treatment of patients with platinum-refractory metastatic urothelial carcinoma; a manageable safety profile was reported in all avelumab-treated patients. These data provide the rationale for therapeutic use of avelumab in metastatic urothelial carcinoma and it has received accelerated US FDA approval in this setting on this basis. (Source: The Lancet Oncology)
Source: The Lancet Oncology - December 4, 2017 Category: Cancer & Oncology Authors: Manish R Patel, John Ellerton, Jeffrey R Infante, Manish Agrawal, Michael Gordon, Raid Aljumaily, Carolyn D Britten, Luc Dirix, Keun-Wook Lee, Mathew Taylor, Patrick Sch öffski, Ding Wang, Alain Ravaud, Arnold B Gelb, Junyuan Xiong, Galit Rosen, James L Tags: Articles Source Type: research
[Comment] JAVELIN: avelumab another spear to fight urothelial carcinoma
Single-agent immune checkpoint blockers targeting programmed death-1 receptor (PD-1) or its ligand PD-L1 have rapidly become standard treatment options for patients with advanced urothelial carcinoma after progression on platinum-based chemotherapy, and are evolving as a first-line option for platinum-ineligible patients.1 –4 Although the proportion of patients achieving a response in the second-line setting is only 15–25%, these responses are generally durable in conjunction with a favorable toxicity profile, which has led to substantial momentum to transition to an immunotherapy-based treatment approach from a c hemo...
Source: The Lancet Oncology - December 4, 2017 Category: Cancer & Oncology Authors: Aly-Khan A Lalani, Bradley A McGregor, Guru P Sonpavde, Toni K Choueiri Tags: Comment Source Type: research
